WITH REDUCED APPETITE, THERE’S
MORE THAN MEETS THE EYE
Don’t wait for weight loss.
Add ENTYCE® (capromorelin oral solution) at the first sign of decreased eating as part of your overall treatment plan.
Long before you see physical changes, small reductions in eating can deprive patients with chronic medical conditions of the essential nutrition they need to support strength and energy, healing and immune response.
ENTYCE is the ONLY FDA-approved veterinary therapeutic labeled for stimulation of appetite in dogs and is an important tool in the clinical management of both chronic and acute medical conditions where appetite is reduced.
Inappetence is more prevalent than you may think, with an average of 14% of U.S. canine patients presenting in clinic with the symptom each year.1
Almost any disease can manifest or develop decreased appetite (hyporexia), complete lack of appetite (anorexia) or changes in appetite (dysrexia). Inappetence can be the first sign, and may be the only sign, that a dog is sick or has an underlying health condition. Prolonged inappetence, if left untreated, can become even more detrimental to the patient than the underlying chronic or acute medical condition.
In addition, inappetence can represent a negative perception of the quality of life to the caregiver, which may be especially distressful and is often perceived as evidence of suffering.
1Aratana Market Research, Sept. 2015
IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.